Skip to main content

Table 1 Clinical characteristics and sustained virologic response rates (SVR)

From: Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin

  All (SVR %) High dose (SVR%) Low dose (SVR%)
Overall population 152 (16.5) 72 (21) 80 (12)
Prior treatment    
   Interferon alone 41 (24) 20 (25) 21 (23)
   Interferon and ribavirin 111 (28) 52 (19) 59 (8)
Hepatitis C Viral genotype    
   1 127 (15) 59 (19) 68 (12)
   Non 1 14 (35) 8 (38) 6 (33)
   Unavailable 11 5 6
Prior response*    
   Non-responder 95 (8) 44 (9) 51 (8)
   Relapser 46 (36) 24 (45) 22 (27)
   Unavailable 11 4 7
  1. *There was significant difference between the prior non-responders and relapsers in all three groups. p = .0001, .001 & .05 respectively.